Common Stock, $0.0001 par value per share
- Symbol
- VOGX
- Exchange
- NASDAQ
- Classification
- COMMON
Current Report · Items 5.02, 7.01, 9.01 · 8-K
Vogenx, Inc.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Richard Gorman as a Director and Employment as Chief Commercial Officer On October 7, 2026, concurrent with his becoming an employee of Vogenx, Inc.…
Press release in this filing
Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer →Company context
We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. Our company was founded in 2021 by experienced leaders with proven expertise developing drugs in the metabolic disease space. Our primary objective is to advance our lead investigational product candidate, mizagliflozin, a selective inhibitor of the sodium-glucose transporter 1, or SGLT1, through clinical development for disorders related to glucose absorption and postprandial dysregulation, and towards regulatory approval.
Registered securities in this filing
VOGENX, INC. · 8-K · Filed 2026-10-09
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Resignation of Richard Gorman as a Director
and Employment as Chief Commercial Officer
On October 7, 2026, concurrent with his becoming
an employee of Vogenx, Inc. (the “Company”) as Chief Commercial Officer, Richard Gorman resigned from the Board of Directors
(“Board”) of the Company and from all committees of the Board on which he served, including the Audit Committee, the Compensation
Committee, and the Nominating and Corporate Governance Committee, effective October 12, 2026. Mr. Gorman’s resignation was not the
result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On October 9, 2026, the Company issued a press
release announcing the resignation of Richard Gorman from the Board and his employment as the Company’s Chief Commercial Officer.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information included in this Current Report
on Form 8-K under this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended,
except as shall be expressly set forth by specific reference in such a filing.
Filed exhibits (1)
Exhibit 99.1 VOGENX, INC. 3901 Barrett Drive, Suite 300 | Raleigh, North Carolina 27609 | Nasdaq: VOGX FOR IMMEDIATE RELEASE Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer Thirty-year biopharmaceutical commercial leader transitions from the Board of Directors to Chief Commercial Officer Appointment strengthens corporate strategy, business development and commercial readiness as the Company advances mizagliflozin following its August 2026 initial public offering RALEIGH, N.C., October 9, 2026 / Vogenx, Inc. (Nasdaq: VOGX), a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced that Richard “Rich” Gorman will join the Vogenx management team as Chief Commercial Officer, effective October 12, 2026. Concurrent with his joining the management team, Mr. Gorman, who has served as an independent member of the Vogenx Board of Directors since 2022, will resign as a member of the Board and its committees. Vogenx will conduct a search to identify a new independent director to join the Board. In this newly created role, Mr. Gorman will lead commercial operations and corporate strategy…
Open exhibit ↗